Syneos Health^® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fosun Pharma USA Inc. (“Fosun Pharma USA“), the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK). As part of the partnership, Syneos Health will provide Full-Service Commercial support through its Syneos One^® team for the launch of Serplulimab, a novel anti-PD-1 antibody for extensive stage small cell lung cancer (ES-SCLC), in the US.

The therapy is the first innovative monoclonal antibody developed by Shanghai Henlius Biotech,Inc. (stock code: 2696.HK) and Fosun Pharma USA has the exclusive right to commercialize Serplulimab in the US upon regulatory approval. Serplulimab has the potential to be the world’s first anti-PD-1 mAb for the first-line treatment of SCLC and is the first asset as part of the partnership with Syneos Health.

Over time, the partnership between the two companies is expected to expand further, continuing to leverage a product development team of experts and full commercial infrastructure within Syneos One to support Fosun Pharma USA’s growth.

“This partnership showcases our ability to provide fit-for-purpose solutions that encompass the entire product development continuum. Our ability to strategize and execute across multiple service lines, including medical affairs and commercial, makes us the premier partner for Fosun Pharma USA,” said Lee Taurman, EVP, Global Head, Syneos One, Syneos Health. “We are strategically supporting the company as its portfolio evolves, working efficiently to optimize Fosun Pharma’s asset portfolio as they expand their Innovative Medicine business in the US.”

Rong Yang, CEO of Fosun Pharma USA and Senior Vice President of Fosun Pharma agreed, “As Fosun Pharma is expanding its innovative medicine presence in the US we are happy to work with industry leader Syneos Health as our strategic partner. Serplulimab is our first innovative medicine asset which is currently in final bridging study stage for ES-SCLC indication in the United States. We look forward to offering the product after regulatory approval to US patients in partnership with Syneos Health.”

Mousumi Sannigrahi, SVP, Head of Commercial, Innovative Medicine, Fosun Pharma USA said, “I am excited about the partnership with Syneos Health and working together to build an innovative commercialization model to best serve our healthcare professionals and patients in today’s changing environment.”

Specifically, for Serplulimab, Syneos Health will provide Medical Affairs, Market Access, Marketing, Sales, and Operations capabilities, as well as staffing, to help Fosun bring new products to market and fill important unmet needs for patients.

Syneos One solutions are unique in the market and can reduce program risk and optimize product development timelines, while maximizing return on investment. Specifically, Syneos One covers the full clinical development, medical affairs and commercialization continuum. These solutions provide small to mid-sized customers with an economic alternative to divesting, out-licensing, or co-promoting assets, and offers large biopharmaceutical customers further opportunity to reduce their fixed-cost infrastructure and can be an alternative approach to developing and promoting non-core and established assets.